Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 20 2025
0mins
Should l Buy ?
Source: PRnewswire
Sirexatamab Study Results: The DeFianCe study demonstrated that sirexatamab significantly improved progression-free survival (PFS) and overall survival (OS) in patients with high levels of DKK1, a negative prognostic factor in colorectal cancer (CRC).
Future Development Plans: Leap Therapeutics plans to advance sirexatamab for CRC treatment, focusing on a biomarker-driven registrational trial, following positive results and a recent financing to support further development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
